Skip to main content
    X

    Xenon Pharmaceuticals Inc (XENE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $34.33
    +0.43 (+1.27%)

    Market Cap: $3.33B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    -5.74%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.15
    Range$-1.29 - $-0.94
    13 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.19+3.7%
    60d ago$-1.16+0.7%
    30d ago$-1.15+0.1%
    7d ago$-1.150.0%
    Current$-1.15
    Revenue Consensus
    $0
    Range$0 - $0
    15 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.12
    Range$-1.42 - $-0.55
    14 analysts
    Revenue Consensus
    $-680380
    Range$-1937500 - $6M
    16 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.12---
    Sep 26EST
    		-$-1.15---
    Jun 26
    Reported Aug 6
    		$-1.11$-1.16+4.31%Beat-3.7%
    Mar 26
    Reported May 7
    		$-1.17$-1.20+2.50%Beat-41.0%
    Dec 25
    Reported Feb 26
    		$-1.31$-1.20-9.17%Miss-56.0%
    Sep 25
    Reported Nov 3
    		$-1.15$-1.16+0.86%Beat-42.0%
    Jun 25
    Reported Aug 11
    		$-1.07$-0.99-8.08%Miss-42.7%
    Mar 25
    Reported May 12
    		$-0.83$-0.90+7.78%Beat-33.9%
    Dec 24
    Reported Feb 27
    		$-0.84$-0.84-0.10%Miss-31.2%
    Sep 24
    Reported Nov 12
    		$-0.81$-0.79-2.53%Miss-11.0%
    Jun 24
    Reported Aug 8
    		$-0.75$-0.68-10.29%Miss-4.2%
    Mar 24
    Reported May 9
    		$-0.62$-0.65+4.62%Beat+1.6%
    Dec 23
    Reported Feb 29
    		$-0.64$-0.76+15.79%Beat-12.3%
    Sep 23
    Reported Nov 8
    		$-0.73$-0.75+2.67%Beat-28.1%
    Jun 23
    Reported Aug 9
    		$-0.72$-0.67-7.46%Miss-30.9%
    Mar 23
    Reported May 9
    		$-0.63$-0.60-5.00%Miss-80.0%
    Dec 22
    Reported Mar 1
    		$-0.57$-0.58+1.72%Beat-18.7%
    Sep 22
    Reported Nov 8
    		$-0.57$-0.53-7.55%Miss-58.3%
    Jun 22
    Reported Aug 9
    		$-0.55$-0.50-10.00%Miss-7.8%
    Mar 22
    Reported May 10
    		$-0.35$-0.41+14.63%Beat+16.7%
    Dec 21
    Reported Mar 1
    		$-0.48$-0.37-29.73%Miss-41.2%
    Sep 21
    Reported Nov 10
    		$-0.36$-0.44+18.18%Beat-44.0%
    Jun 21
    Reported Aug 11
    		$-0.51$-0.49-4.08%Miss-10308.2%
    Mar 21
    Reported May 11
    		$-0.42$-0.39-7.69%Miss-90.9%
    Dec 20
    Reported Mar 1
    		$-0.34$-0.40+15.00%Beat+19.0%
    Sep 20
    Reported Nov 5
    		$-0.25$-0.17-47.06%Miss+24.2%
    Jun 20
    Reported Aug 6
    		$-0.00N/A+97.55%Beat+98.7%
    Mar 20
    Reported May 21
    		$-0.22$-0.31+29.03%Beat+47.6%
    Dec 19
    Reported Mar 9
    		$-0.42$-0.48+12.50%Beat-44.8%
    Sep 19
    Reported Nov 5
    		$-0.33$-0.46+28.26%Beat+47.6%
    Jun 19
    Reported Aug 6
    		$-0.37$-0.45+17.78%Beat+17.8%
    Mar 19
    Reported May 7
    		$-0.42$-0.37-13.51%Miss+8.7%
    Dec 18
    Reported Mar 6
    		$-0.29$-0.37+21.62%Beat+35.6%
    Sep 18
    Reported Nov 6
    		$-0.63$-0.40-57.50%Miss-46.5%
    Jun 18
    Reported Aug 7
    		$-0.45$-0.49+8.16%Beat-9.8%
    Mar 18
    Reported May 8
    		$-0.46$-0.48+4.17%Beat-9.5%
    Dec 17
    Reported Mar 7
    		$-0.45$-0.11-309.09%Miss-40.6%
    Sep 17
    Reported Nov 7
    		$-0.43$-0.39-10.26%Miss-
    Jun 17
    Reported Aug 3
    		$-0.41$-0.39-5.13%Miss-
    Mar 17
    Reported May 9
    		$-0.42$-0.38-10.53%Miss-
    Dec 16
    Reported Mar 8
    		$-0.32$-0.42+23.81%Beat-

    Key Metrics

    Valuation
    P/E Ratio-7.24EV/EBITDAN/A
    Price/FCF-10.10xFCF Yield-9.90%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-43.60%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio21.02xQuick Ratio21.02x
    Trading Statistics
    Beta0.60Avg Volume2.92M
    52-Week High$72.6652-Week Low$33.52

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$35.96
    SMA 20$36.96
    SMA 50$51.33
    SMA 200$52.71
    EMA 10$35.99
    EMA 20$39.35
    EMA 50$47.37
    EMA 200$51.13

    MACD

    Line: -4.86Signal: -5.29Hist: 0.43

    ADX

    ADX: 50.4+DI: 10.6-DI: 42.2

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$35.76

    Bollinger Bands

    Upper Band$40.16
    Lower Band$33.75
    %B Position1735%(Upper)
    Band Width0.09

    RSI (14-Day)

    Oversold
    22.1

    Momentum Oscillators

    Stoch %K6.4
    Stoch %D9.6
    Williams %R-87.3
    ROC (10d)-11.8%
    Momentum-4.60
    CCI (20d)-139.2
    MFI (14d)41.7

    Volatility Measures

    ATR (14d)$1.82(5.3%)
    StdDev (20d)1.60
    Hist Vol113.7%(High)

    Volume Flow

    VWAP$34.44
    OBV-8.5M
    AD Line-19.7M
    CMF (20d)-0.218

    Volume Metrics

    Avg Vol (20d)3.1M
    Vol Ratio0.5x
    VWMA (20d)$37.91

    Pivot Points

    R3$35.97
    R2$35.41
    R1$34.65
    Pivot Point$34.09
    S1$33.33
    S2$32.77
    S3$32.01

    Advanced Oscillators

    TSI-57.60
    Ultimate Osc42.9
    KST-328.31

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$7.50M$2.52M$0$0$0$5.38M$0
    Cost of Revenue$0$0$611,000$0$0$0$633,000$0$0$0$851,000$0
    Gross Profit$0$0$-611,000$0$0$7.50M$1.26M$0$0$0$4.53M$0
    Operating Expenses$123.16M$112.33M$109.77M$96.34M$94.23M$80.24M$77.48M$73.68M$69.10M$59.04M$53.70M$55.68M
    R&D$99.22M$88.51M$87.70M$77.05M$74.98M$61.20M$59.47M$56.97M$49.70M$44.25M$41.08M$42.88M
    SG&A$23.93M$23.82M$22.07M$19.28M$19.24M$19.04M$18.00M$16.71M$19.40M$14.79M$12.62M$12.80M
    Operating Income$-123,155,000$-112,328,000$-109,767,000$-96,336,000$-94,229,000$-72,738,000$-77,477,000$-73,676,000$-69,104,000$-59,041,000$-53,695,000$-55,684,000
    Interest Income$12.14M$6.91M$5.34M$6.21M$7.20M$8.08M$9.42M$10.33M$10.84M$11.36M$8.69M$6.98M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-111,321,000$-104,873,000$-104,723,000$-90,219,000$-85,332,000$-64,620,000$-69,533,000$-63,110,000$-58,257,000$-47,519,000$-44,948,000$-48,619,000
    Income Tax Expense$-585,000$-2,571,000$538,000$677,000$-626,000$427,000$-3,848,000$-320,000$-333,000$412,000$-205,000$-157,000
    Net Income$-110,736,000$-102,302,000$-105,261,000$-90,896,000$-84,706,000$-65,047,000$-65,685,000$-62,790,000$-57,924,000$-47,931,000$-44,743,000$-48,462,000
    EBITDA$-122,908,000$-111,193,000$-109,452,000$-95,784,000$-91,899,000$-72,044,000$-78,289,000$-72,772,000$-68,453,000$-58,288,000$-54,268,000$-53,867,000
    EBIT$-123,466,000$-111,780,000$-110,063,000$-96,425,000$-92,531,000$-72,703,000$-78,955,000$-73,439,000$-69,094,000$-58,874,000$-53,639,000$-55,601,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XENE

    News

    XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

    Xenon Pharmaceuticals (XENE) faces investor concern after temporarily pausing enrollment in its late-stage depression trials due to unexpected neurological and psychiatric side effects from its lead asset...

    TradingView•10/15/26•Somewhat-Bearish

    Xenon grants 28,350 awards as Xenon Pharmaceuticals stock is valued at USD 3.3 billion

    Xenon Pharmaceuticals granted 28,350 equity awards on October 2, 2026, as the company's stock is valued at USD 3.3 billion. This comes after the submission of an application to the FDA for azetukalner in focal seizures...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Xenon Pharmaceuticals stock hits 52-week low at 35.04 USD

    Xenon Pharmaceuticals (XENE) stock has dropped to a 52-week low of $35.04, reflecting a significant decline over the past year. Despite the current undervaluation and oversold RSI...

    Investing.com•10/13/26•Somewhat-Bearish

    Xenon Pharmaceuticals stock hits 52-week low at 35.04 USD By Investing.com

    Xenon Pharmaceuticals Inc. (XENE) stock has dropped to a 52-week low of $35.04, reflecting a 39% loss over the past six months and a 13.31% decline over the year. Despite the recent downturn and a voluntary pause in some...

    Investing.com Canada•10/13/26•Bearish

    Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call

    Xenon Pharmaceuticals reported strong Q2 2026 financial results, with $1.2 billion in cash, extending operations funding into 2029. The company is on track to submit a New Drug Application (NDA) for azetukalner (AZK)...

    Benzinga•10/12/26•Bullish

    XENE Valuation and Fair Value

    P/E
    -7.2x
    P/FCF
    -10.1x
    PEG
    -0.1x
    P/B
    2.8x
    See GNG's fair value

    XENE Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -43.6%
    FCF yield
    -9.9%

    XENE Competitors

    CompanyTicker
    Tarsus Pharmaceuticals IncTARS
    Arcutis Biotherapeutics IncARQT
    CareDx IncCDNA
    Ideaya Biosciences IncIDYA
    Viking Therapeutics IncVKTX
    Warby Parker IncWRBY
    Cidara Therapeutics IncCDTX
    Celcuity LLCCELC

    Sector: Healthcare

    XENE Analyst Ratings

    Consensus
    Buy
    Analysts
    19
    Strong Buy
    3
    Buy
    15
    Hold
    1
    Sell
    0
    Strong Sell
    0

    XENE Bull Case vs Bear Case

    Bull case

    • 94.7% of XENE's analyst ratings are Buy or Strong Buy.

    Bear case

    • XENE's quarterly revenue changed -100.0% year over year.

    XENE Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -0.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.15
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About XENE

    Does XENE pay dividends?

    Xenon Pharmaceuticals Inc (XENE) does not currently pay a regular dividend.

    What is XENE's market cap?

    Xenon Pharmaceuticals Inc (XENE) has a market capitalization of $3.33B with a current stock price of $34.33.

    Related stocks

    Sector: Healthcare

    All stocks starting with X

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In